Search results
What Is Severe Asthma?
Health via Yahoo News· 1 month agoRealPeopleGroup / Getty Images Medically reviewed by Reza Samad, MD Severe asthma is the term used for asthma that is difficult to treat and control....
Severe Asthma Patients on Ways Their Doctors Could Improve Treatment
Time via Yahoo News· 1 year agoCredit - shutjane—Getty Images Approximately 25 million people in the U.S. have asthma, according to...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 6 days agoAstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically...
Flovent asthma inhalers pulled from shelves and replaced with generic Jan. 1
USA TODAY via Yahoo News· 4 months agoOne of the most widely-used asthma and breathing treatments for over 20 years is being taken off the...
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Zacks via Yahoo Finance· 1 year agoThe CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of...
How Is Asthma Diagnosed?
Health via Yahoo News· 12 months agoAsthma is a chronic lung disease characterized by inflammation and narrowing of the airways, causing symptoms like shortness of breath, wheezing,...
AstraZeneca drug fails one main goal in study of chronic immune disease
Reuters via Yahoo News· 2 years agoThe condition, eosinophilic esophagitis, is characterised by inflammation and damage to the...
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
Zacks via Yahoo Finance· 2 years agoAstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma...
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks via Yahoo Finance· 3 weeks agoAstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra...
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Zacks via Yahoo Finance· 5 months agoRegeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced positive study data on the...